



Medicine Supply Notification

MSN/2025/023

Fentanyl (**Durogesic® DTrans®**) 12micrograms/hour, 25micrograms/hour, 50micrograms/hour, 75micrograms/hour, and 100micrograms/hour patches
Tier 2 – medium impact*

Date of issue: 15/04/2025

Link: [Medicines Supply Tool](#)

Summary

- Durogesic® DTrans® 75micrograms/hour patches are out of stock until December 2025.
- Durogesic® DTrans® 12micrograms/hour patches will be out of stock from late April until December 2025.
- Durogesic® DTrans® 25micrograms/hour and 50micrograms/hour patches will be out of stock from late May until December 2025.
- Durogesic® DTrans® 100micrograms/hour patches will be out of stock from late June until December 2025.
- Alternative brands of fentanyl **matrix** patches (Fencino®, Matrifen®, Mezolar®, Opiodur®, Yemex®) remain available and can support increased demand.

Actions Required

Prescribers should not initiate patients on Durogesic® DTrans® (all strengths) until the supply issues have resolved.

Where patients have insufficient supplies to last until the re-supply dates, clinicians should:

- review patients and consider prescribing an alternative brand of fentanyl **matrix** patch that is available including: Fencino®, Matrifen®, Mezolar®, Opiodur®, Yemex® (see Supporting Information);
- monitor and clinically assess the patient's response and titrate dose if required;
- ensure patients are counselled on the change in brand and are not intolerant to any of the patch excipients (see Supporting information).

Supporting information

Clinical Information

Fentanyl transdermal patches are available as matrix (drug embedded in an adhesive matrix with the release rate determined by the physical properties of the matrix) and reservoir (drug held in a reservoir with a rate-limiting membrane to control release of drug) formulations. These two patch formulations should **not** be used interchangeably. To avoid confusion and ensure consistency of supply to patients, it is recommended that all fentanyl patches are prescribed by brand name.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Durogesic® DTrans® is a **matrix** patch licensed for management of severe chronic pain that requires continuous long-term opioid administration.

When prescribing an alternative brand of fentanyl patch, the summary of product characteristics (SmPC) should be consulted for cautions, contraindications and excipients, as these may vary between products.

CAUTION: Prescribers should be aware that Fencino® and Yemex® fentanyl patches contain soya oil and are contraindicated in patients with peanut/ soya allergy.

Links to further information

[SmPC Durogesic® DTrans® \(fentanyl\) patches](#)

[SmPC Fencino® \(fentanyl\) patches](#)

[SmPC Matrifen® \(fentanyl\) patches](#)

[SmPC Mezolar® \(fentanyl\) patches](#)

[SmPC Opiodur® \(fentanyl\) patches](#)

[SmPC Yemex®\(fentanyl\) patches](#)

[BNF Fentanyl](#)

[Fentanyl patches | Right Decisions](#)

[PrescQIPP - Opioid Patches](#)

[SPS - Example medicines to prescribe by brand name in primary care](#)

[MHRA - Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children](#)

[SPS- Using transdermal patches safely in healthcare settings](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.